Mr Peter Giannopoulos appointed as CEO of Cell Therapies Pty Ltd

Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the Asia Pacific region, is delighted to announce the appointment of Mr Peter Giannopoulos as the company’s new Chief Executive Officer.

Mr Giannopoulos has over 20 years’ experience across the Australian healthcare ecosystem, with strong expertise in operations, strategic business development and delivering innovative growth opportunities in the pharmaceutical and biotechnology industry. His career has been driven by his strong desire to improve outcomes for patients, customers, and communities.

Cell Therapies Chair Associate Professor Leslie Reti AM said the appointment was exciting for Cell Therapies and majority shareholder, the Peter MacCallum Cancer Centre. “We look forward to Peter leading our high-performing team into an exciting phase of its growth and development,” he said.

Mr Giannopoulos will commence as Cell Therapies’ Chief Executive Officer on 1 June 2021, succeeding Associate Professor Dominic Wall, Chief Scientific Officer and interim CEO. The Cell Therapies Pty Ltd Board of Directors would like to take this opportunity to thank Associate Professor Wall for his leadership during the transition period.